Title
A STRUCTURE BASED DRUG DESIGN STUDY ON VEGFR2 INHIBITORS: Exploiting Molecular Docking and InSilico Validation,Used
Sold by Ergodebooks, an authorized reseller.
Returns accepted within 30 days | support@ergodebooks.com
Shipping Information
- Free Standard Shipping — United States only
- Processing Time: 1–3 business days
- Estimated Delivery: 3–5 business days after dispatch
- Double-boxed, fully insured & discreetly packaged
- Tracking number sent via email once dispatched
- Orders over $250 require signature upon delivery. Taxes calculated at checkout.
Returns & Refund
Returns accepted within 30 days of delivery.
Damaged or Defective Item
Free return shipping + replacement or full refund
Wrong Item Received
Free return shipping + replacement or full refund
Change of Mind
Return shipping at customer's expense · 25% restocking fee applies
Payment Option
VEGF (Vascular Endothelial Growth Factor) is a potent angiogenic signal implicated with a key role in several pathological processes, including tumour vascularization, angiogenesis, and endothelial cell growth. The members of VEGF family bind to tyrosine kinase receptors on the cell surface to initiate a signalling cascade. VEGFR2 is one such Receptor Tyrosine Kinase(RTK) that is found to mediate a majority of the cellular responses to VEGF. A structure based drug design study was performed on VEGFR2 inhibitors based on the article ?Hetaryl imidazoles: A novel dual inhibitors of VEGF receptors 1 and 2?. The target protein was retrieved from the Protein Data Bank (I.D. 2OH4), based on the Ramachandran plot. The structures of reported inhibitors were obtained in 3D format using standard software packages. These 3D analogues were docked to the protein of choice using Molegro Virtual Docker. Based on a correlation between experimentally obtained log IC50 values and the results of the docking study, direct drug design was carried out. Novel inhibitors with significantly higher moldock scores were obtained with simple modifications to the original structure.
⚠️ WARNING (California Proposition 65):
This product may contain chemicals known to the State of California to cause cancer, birth defects, or other reproductive harm.
For more information, please visit www.P65Warnings.ca.gov.